Could Marinus Pharmaceuticals, Inc. (MRNS) Decline After Today’s Significant Increase?

February 15, 2018 - By Peter Erickson

Investors sentiment increased to 2.8 in 2017 Q3. Its up 2.26, from 0.54 in 2017Q2. It increased, as 8 investors sold Marinus Pharmaceuticals, Inc. shares while 2 reduced holdings. 20 funds opened positions while 8 raised stakes. 18.97 million shares or 171.42% more from 6.99 million shares in 2017Q2 were reported.
Deutsche State Bank Ag reported 200 shares. Caxton accumulated 0.1% or 16,198 shares. Ellington Limited Liability Corporation has 45,100 shares. Fincl Bank Of New York Mellon Corporation reported 21,842 shares. Iguana Healthcare Mngmt Limited Liability Corporation invested in 175,000 shares or 0.57% of the stock. Blackrock Incorporated has 0% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Franklin Res stated it has 2.18M shares. Arrowmark Colorado stated it has 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Adage Ptnrs Grp Limited Company invested in 600,000 shares. Northern Trust Corporation invested in 45,678 shares or 0% of the stock. Susquehanna Int Grp Inc Incorporated Llp has 0% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). 129,000 were accumulated by Atika Cap Mngmt Limited. Orbimed has 0.03% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) for 567,600 shares. Perceptive Advsr Lc stated it has 0.33% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Granite Point Capital Limited Partnership reported 2.68M shares or 3.32% of all its holdings.

Since December 15, 2017, it had 0 buys, and 2 insider sales for $10.05 million activity. The insider Bain Capital Life Sciences Investors – LLC sold $10.02M.

The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) is a huge mover today! The stock increased 6.51% or $0.396 during the last trading session, reaching $6.476. About 1.23M shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has declined 74.89% since February 15, 2017 and is downtrending. It has underperformed by 91.59% the S&P500.
The move comes after 5 months positive chart setup for the $261.83 million company. It was reported on Feb, 15 by Barchart.com. We have $7.06 PT which if reached, will make NASDAQ:MRNS worth $23.56 million more.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Ratings Coverage

Among 4 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Marinus Pharmaceuticals had 9 analyst reports since August 5, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, October 30 by Oppenheimer. The company was downgraded on Tuesday, June 14 by RBC Capital Markets. On Tuesday, March 8 the stock rating was maintained by Stifel Nicolaus with “Buy”. On Thursday, December 17 the stock rating was initiated by RBC Capital Markets with “Outperform”. On Tuesday, November 17 the stock rating was initiated by Jefferies with “Buy”. The rating was maintained by Jefferies on Wednesday, August 10 with “Buy”. The rating was downgraded by Oppenheimer on Tuesday, June 14 to “Perform”. The company was maintained on Wednesday, August 5 by Oppenheimer. The company was maintained on Tuesday, June 14 by Jefferies.

More news for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) were recently published by: Gurufocus.com, which released: “EcoR1 Capital, LLC Buys Dicerna Pharmaceuticals Inc, Apellis Pharmaceuticals …” on February 15, 2018. Globenewswire.com‘s article titled: “Marinus Pharmaceuticals to Attend Upcoming Investor Conferences” and published on February 07, 2018 is yet another important article.

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $261.83 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: